We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Clear all

Refine your search

Content type

3 results found


Haynes and Boone LLP | USA | 20 Jun 2013

Implications for personalized medicine after Myriad

On June 13, 2013, in the highly anticipated decision for Ass'n for Molecular Pathology v. Myriad Genetics, Inc., the Supreme Court shed some light on

Previous page 1 Next page